共 10 条
Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience
被引:27
作者:

Momose, Mami
论文数: 0 引用数: 0
h-index: 0
机构:
Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan

Asahina, Akihiko
论文数: 0 引用数: 0
h-index: 0
机构:
Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan

Umezawa, Yoshinori
论文数: 0 引用数: 0
h-index: 0
机构:
Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan

Nakagawa, Hidemi
论文数: 0 引用数: 0
h-index: 0
机构:
Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan
机构:
[1] Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan
关键词:
biologics;
efficacy;
psoriasis;
safety;
secukinumab;
SEVERE PLAQUE PSORIASIS;
MODERATE;
PHASE-3;
D O I:
10.1111/1346-8138.14145
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin-17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess long-term efficacy and safety of secukinumab for 52 weeks in real-world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bio-switched patients. Psoriasis Area and Severity Index (PASI) 75 and PASI-90 responses were 80% and 64% at week 12, 77% and 65% at week 24, and 76% and 58% at week 52, respectively. No significant differences were observed in efficacy between bio-naive and bio-switched patients. Arthralgia showed improvement by week 12 in all patients with psoriatic arthritis with a reduction of serum C-reactive protein level. Treatment was discontinued in 22% (18/83), including eight patients with no improvement or exacerbation of cutaneous manifestations, one patient with new onset of arthritis and two patients with transient infection. Overall, secukinumab showed a sustained clinical response with an acceptable safety profile through week 52 in Japanese psoriatic patients.
引用
收藏
页码:318 / 321
页数:4
相关论文
共 10 条
- [1] Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations[J]. NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (12) : 743 - 750Gossec, Laure论文数: 0 引用数: 0 h-index: 0机构: Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, France Pitie Salpetriere Hop, AP HP, Serv Rhumatol, 47-83 Blvd Hop, F-75013 Paris, France Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, FranceCoates, Laura C.论文数: 0 引用数: 0 h-index: 0机构: Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Fac Med & Hlth, Leeds LS7 4SA, W Yorkshire, England Chapel Allerton Hosp, Leeds Musculoskeletal Biomed Res Unit, 2nd Floor,Chapeltown Rd, Leeds LS7 4SA, W Yorkshire, England Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, Francede Wit, Maarten论文数: 0 引用数: 0 h-index: 0机构: Vrije Univ, Med Ctr, Dept Med Humanities, POB 7057, NL-1007 MB Amsterdam, Netherlands Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, FranceKavanaugh, Arthur论文数: 0 引用数: 0 h-index: 0机构: Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, France论文数: 引用数: h-index:机构:Mease, Philip J.论文数: 0 引用数: 0 h-index: 0机构: Swedish Med Ctr, Rheumatol Clin Res Div, 601 Broadway,Suite 600, Seattle, WA 98102 USA Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, FranceRitchlin, Christopher T.论文数: 0 引用数: 0 h-index: 0机构: Univ Rochester, Med Ctr, Div Allergy Immunol & Rheumatol, Dept Med, 601 Elmwood Ave,BOX 695, Rochester, NY 14642 USA Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, Francevan der Heijde, Desiree论文数: 0 引用数: 0 h-index: 0机构: Leiden Univ, Dept Rheumatol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, FranceSmolen, Josef S.论文数: 0 引用数: 0 h-index: 0机构: Med Univ Vienna, Div Rheumatol, Dept Med 3, Waehringer Guertel 18-20, A-1090 Vienna, Austria Hietzing Hosp, Dept Med 2, Wolkersbergenstr 1, A-1130 Vienna, Austria Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, 4 Pl Jussieu, F-75005 Paris, France
- [2] Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study[J]. JOURNAL OF DERMATOLOGY, 2016, 43 (09) : 1011 - 1017Imafuku, Shinichi论文数: 0 引用数: 0 h-index: 0机构: Fukuoka Univ, Dept Dermatol, Fukuoka, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanHonma, Masaru论文数: 0 引用数: 0 h-index: 0机构: Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanOkubo, Yukari论文数: 0 引用数: 0 h-index: 0机构: Tokyo Med Univ, Dept Dermatol, Tokyo, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanKomine, Mayumi论文数: 0 引用数: 0 h-index: 0机构: Jichi Med Univ, Dept Dermatol, Shimotsuke, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanOhtsuki, Mamitaro论文数: 0 引用数: 0 h-index: 0机构: Jichi Med Univ, Dept Dermatol, Shimotsuke, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanMorita, Akimichi论文数: 0 引用数: 0 h-index: 0机构: Nagoya City Univ, Dept Dermatol, Nagoya, Aichi, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanSeko, Noriko论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Dept Biometr & Stat Sci, Tokyo, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanKawashima, Naoko论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Clin Trial Management Grp, Tokyo, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanIto, Saori论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Dept Clin Resource & Dev, Tokyo, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanShima, Tomohiro论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Dept Immunol & Dermatol Clin Franchise, Tokyo, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, JapanNakagawa, Hidemi论文数: 0 引用数: 0 h-index: 0机构: Jikei Univ, Sch Med, Dept Dermatol, Tokyo, Japan Fukuoka Univ, Dept Dermatol, Fukuoka, Japan
- [3] Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (04) : 326 - 338Langley, Richard G.论文数: 0 引用数: 0 h-index: 0机构: Dalhousie Univ, Halifax, NS B3H 1V7, Canada Dalhousie Univ, Halifax, NS B3H 1V7, CanadaElewski, Boni E.论文数: 0 引用数: 0 h-index: 0机构: Univ Alabama Birmingham, Birmingham, AL USA Dalhousie Univ, Halifax, NS B3H 1V7, CanadaLebwohl, Mark论文数: 0 引用数: 0 h-index: 0机构: Mt Sinai Hosp, New York, NY 10029 USA Dalhousie Univ, Halifax, NS B3H 1V7, CanadaReich, Kristian论文数: 0 引用数: 0 h-index: 0机构: Dermatologikum Hamburg, Hamburg, Germany Univ Gottingen, D-37073 Gottingen, Germany Dalhousie Univ, Halifax, NS B3H 1V7, CanadaGriffiths, Christopher E. M.论文数: 0 引用数: 0 h-index: 0机构: Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp, Dermatol Ctr, Manchester, Lancs, England Dalhousie Univ, Halifax, NS B3H 1V7, CanadaPapp, Kim论文数: 0 引用数: 0 h-index: 0机构: Clin Res, Waterloo, ON, Canada Prob Med Res, Waterloo, ON, Canada Dalhousie Univ, Halifax, NS B3H 1V7, CanadaPuig, Lluis论文数: 0 引用数: 0 h-index: 0机构: Hosp Santa Creu & Sant Pau, Barcelona, Spain Dalhousie Univ, Halifax, NS B3H 1V7, CanadaNakagawa, Hidemi论文数: 0 引用数: 0 h-index: 0机构: Jikei Univ, Sch Med, Tokyo, Japan Dalhousie Univ, Halifax, NS B3H 1V7, CanadaSpelman, Lynda论文数: 0 引用数: 0 h-index: 0机构: Prob Med Res, Waterloo, ON, Canada Verac Clin Res, Woolloongabba, Qld, Australia Dalhousie Univ, Halifax, NS B3H 1V7, CanadaSigurgeirsson, Bardur论文数: 0 引用数: 0 h-index: 0机构: Univ Iceland, Dept Dermatol, Fac Med, Reykjavik, Iceland Dalhousie Univ, Halifax, NS B3H 1V7, CanadaRivas, Enrique论文数: 0 引用数: 0 h-index: 0机构: Dermos, Guatemala City, Guatemala Dalhousie Univ, Halifax, NS B3H 1V7, CanadaTsai, Tsen-Fang论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan Dalhousie Univ, Halifax, NS B3H 1V7, CanadaWasel, Norman论文数: 0 引用数: 0 h-index: 0机构: Strat Med & Prob Med Res, Edmonton, AB, Canada Dalhousie Univ, Halifax, NS B3H 1V7, CanadaTyring, Stephen论文数: 0 引用数: 0 h-index: 0机构: Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA Ctr Clin Studies, Houston, TX USA Dalhousie Univ, Halifax, NS B3H 1V7, CanadaSalko, Thomas论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, Basel, Switzerland Dalhousie Univ, Halifax, NS B3H 1V7, CanadaHampele, Isabelle论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, Basel, Switzerland Dalhousie Univ, Halifax, NS B3H 1V7, CanadaNotter, Marianne论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, Basel, Switzerland Dalhousie Univ, Halifax, NS B3H 1V7, CanadaKarpov, Alexander论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, Basel, Switzerland Dalhousie Univ, Halifax, NS B3H 1V7, CanadaHelou, Silvia论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, Basel, Switzerland Dalhousie Univ, Halifax, NS B3H 1V7, CanadaPapavassilis, Charis论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, Basel, Switzerland Dalhousie Univ, Halifax, NS B3H 1V7, Canada
- [4] Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. LANCET, 2015, 386 (9999) : 1137 - 1146McInnes, Iain B.论文数: 0 引用数: 0 h-index: 0机构: Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandMease, Philip J.论文数: 0 引用数: 0 h-index: 0机构: Swedish Med Ctr, Seattle, WA USA Univ Washington, Seattle, WA 98195 USA Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandKirkham, Bruce论文数: 0 引用数: 0 h-index: 0机构: Guys & St Thomas NHS Fdn Trust, London, England Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandKavanaugh, Arthur论文数: 0 引用数: 0 h-index: 0机构: San Diego Sch Med, Dept Internal Med, Div Rheumatol Allergy & Immunol, San Diego, CA USA Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandRitchlin, Christopher T.论文数: 0 引用数: 0 h-index: 0机构: Univ Rochester, Allergy Immunol & Rheumatol Div, Rochester, NY USA Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandRahman, Proton论文数: 0 引用数: 0 h-index: 0机构: Mem Univ, St John, NF, Canada Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandVan der Heijde, Desiree论文数: 0 引用数: 0 h-index: 0机构: Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandLandewe, Robert论文数: 0 引用数: 0 h-index: 0机构: Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands Atrium Med Ctr, Heerlen, Netherlands Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandConaghan, Philip G.论文数: 0 引用数: 0 h-index: 0机构: NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England Univ Leeds, Leeds, W Yorkshire, England Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandGottlieb, Alice B.论文数: 0 引用数: 0 h-index: 0机构: Tufts Med Ctr, Dept Dermatol, Boston, MA USA Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandRichards, Hanno论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, Basel, Switzerland Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandPricop, Luminita论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, E Hanover, NJ USA Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandLigozio, Gregory论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, E Hanover, NJ USA Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandPatekar, Manmath论文数: 0 引用数: 0 h-index: 0机构: Novartis Healthcare, Hyderabad, Andhra Pradesh, India Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, ScotlandMpofu, Shephard论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, Basel, Switzerland Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland
- [5] Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch[J]. JOURNAL OF DERMATOLOGY, 2017, 44 (10) : 1105 - 1111Ohtsuki, Mamitaro论文数: 0 引用数: 0 h-index: 0机构: Jichi Med Univ, Shimotsuke, Tochigi, Japan Jichi Med Univ, Shimotsuke, Tochigi, JapanMorita, Akimichi论文数: 0 引用数: 0 h-index: 0机构: Nagoya City Univ, Nagoya, Aichi, Japan Jichi Med Univ, Shimotsuke, Tochigi, JapanIgarashi, Atsuyuki论文数: 0 引用数: 0 h-index: 0机构: NTT Med Ctr Tokyo, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi, Japan论文数: 引用数: h-index:机构:Tada, Yayoi论文数: 0 引用数: 0 h-index: 0机构: Teikyo Univ, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi, JapanFujita, Hiroyuki论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi, JapanFujishige, Ayako论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi, JapanYamaguchi, Masako论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi, JapanTeshima, Rie论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi, JapanTani, Yumiko论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi, JapanNakagawa, Hidemi论文数: 0 引用数: 0 h-index: 0机构: Jikei Univ, Sch Med, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi, Japan
- [6] Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study[J]. JOURNAL OF DERMATOLOGY, 2014, 41 (12) : 1039 - 1046Ohtsuki, Mamitaro论文数: 0 引用数: 0 h-index: 0机构: Jichi Med Univ, Shimotsuke, Tochigi 3290498, Japan Jichi Med Univ, Shimotsuke, Tochigi 3290498, JapanMorita, Akimichi论文数: 0 引用数: 0 h-index: 0机构: Nagoya City Univ, Nagoya, Aichi, Japan Jichi Med Univ, Shimotsuke, Tochigi 3290498, JapanAbe, Masatoshi论文数: 0 引用数: 0 h-index: 0机构: Sapporo Skin Clin, Sapporo, Hokkaido, Japan Jichi Med Univ, Shimotsuke, Tochigi 3290498, JapanTakahashi, Hidetoshi论文数: 0 引用数: 0 h-index: 0机构: Takagi Dermatol Clin, Obihiro, Hokkaido, Japan Jichi Med Univ, Shimotsuke, Tochigi 3290498, JapanSeko, Noriko论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi 3290498, JapanKarpov, Alexander论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Jichi Med Univ, Shimotsuke, Tochigi 3290498, JapanShima, Tomohiro论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma KK, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi 3290498, JapanPapavassilis, Charis论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Jichi Med Univ, Shimotsuke, Tochigi 3290498, JapanNakagawa, Hidemi论文数: 0 引用数: 0 h-index: 0机构: Jikei Univ, Sch Med, Tokyo, Japan Jichi Med Univ, Shimotsuke, Tochigi 3290498, Japan
- [7] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis[J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 752 - 758Reich, K.论文数: 0 引用数: 0 h-index: 0机构: Dermatologikum Hamburg, Hamburg, Germany SCIderm Res Inst, Hamburg, Germany Dermatologikum Hamburg, Hamburg, GermanyBlauvelt, A.论文数: 0 引用数: 0 h-index: 0机构: Oregon Med Res Ctr, Portland, OR USA Dermatologikum Hamburg, Hamburg, GermanyArmstrong, A.论文数: 0 引用数: 0 h-index: 0机构: Univ Southern Calif, Los Angeles, CA USA Dermatologikum Hamburg, Hamburg, GermanyLangley, R. G.论文数: 0 引用数: 0 h-index: 0机构: Dalhousie Univ, Halifax, NS, Canada Dermatologikum Hamburg, Hamburg, GermanyFox, T.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Dermatologikum Hamburg, Hamburg, GermanyHuang, J.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, E Hanover, NJ USA Dermatologikum Hamburg, Hamburg, GermanyPapavassilis, C.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Dermatologikum Hamburg, Hamburg, GermanyLiang, E.论文数: 0 引用数: 0 h-index: 0机构: Novartis Inst Biomed Res, Basel, Switzerland Dermatologikum Hamburg, Hamburg, GermanyLloyd, P.论文数: 0 引用数: 0 h-index: 0机构: Novartis Inst Biomed Res, Basel, Switzerland Dermatologikum Hamburg, Hamburg, GermanyBruin, G.论文数: 0 引用数: 0 h-index: 0机构: Novartis Inst Biomed Res, Basel, Switzerland Dermatologikum Hamburg, Hamburg, Germany
- [8] Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study[J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 402 - 411Rich, P.论文数: 0 引用数: 0 h-index: 0机构: Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA论文数: 引用数: h-index:机构:论文数: 引用数: h-index:机构:Ortonne, J. -P.论文数: 0 引用数: 0 h-index: 0机构: CHU Nice, Hosp Archet 2, Dept Dermatol, Nice, France Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA论文数: 引用数: h-index:机构:Schopf, R. E.论文数: 0 引用数: 0 h-index: 0机构: Johannes Gutenberg Univ Mainz, Dept Dermatol, D-55122 Mainz, Germany Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USAMorita, A.论文数: 0 引用数: 0 h-index: 0机构: Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USARoseau, K.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USAHarfst, E.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USAGuettner, A.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USAMachacek, M.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USAPapavassilis, C.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
- [9] Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)[J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (03) : 777 - 787Thaci, D.论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, Germany Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, GermanyHumeniuk, J.论文数: 0 引用数: 0 h-index: 0机构: Humeniuk Dermatol, Greenville, SC USA Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, GermanyFrambach, Y.论文数: 0 引用数: 0 h-index: 0机构: Hanse Klin, Lubeck, Germany Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, GermanyBissonnette, R.论文数: 0 引用数: 0 h-index: 0机构: Innovaderm Res, Montreal, PQ, Canada Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, GermanyGoodman, J. J.论文数: 0 引用数: 0 h-index: 0机构: Palm Beach Res Ctr, W Palm Beach, FL USA Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, GermanyShevade, S.论文数: 0 引用数: 0 h-index: 0机构: Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, GermanyGong, Y.论文数: 0 引用数: 0 h-index: 0机构: Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, GermanyPapavassilis, C.论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Univ Hosp Schleswig Holstein, Comprehens Ctr Inflammat Med, D-23538 Lubeck, Germany
- [10] Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (01) : 83 - +van de Kerkhof, Peter C. M.论文数: 0 引用数: 0 h-index: 0机构: Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsGriffiths, Christopher E. M.论文数: 0 引用数: 0 h-index: 0机构: Univ Manchester, Manchester Acad Hlth Sci Ctr, Dermatol Ctr, Salford Royal Hosp, Manchester, Lancs, England Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsReich, Kristian论文数: 0 引用数: 0 h-index: 0机构: Dermatologikum Hamburg, Gottingen, Germany Univ Gottingen, D-37073 Gottingen, Germany Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsLeonardi, Craig L.论文数: 0 引用数: 0 h-index: 0机构: St Louis Univ, Hlth Sci Ctr, St Louis, MO 63103 USA Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsBlauvelt, Andrew论文数: 0 引用数: 0 h-index: 0机构: Oregon Med Res Ctr, Portland, OR USA Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsTsai, Tsen-Fang论文数: 0 引用数: 0 h-index: 0机构: Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Taipei 10764, Taiwan Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsGong, Yankun论文数: 0 引用数: 0 h-index: 0机构: Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsHuang, Jiaqing论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharmaceut, E Hanover, NJ USA Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsPapavassilis, Charis论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, NetherlandsFox, Todd论文数: 0 引用数: 0 h-index: 0机构: Novartis Pharma AG, Basel, Switzerland Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands